News

BioVaxys Announces Interim Results From Preclinical Study of its SARS-CoV-2 Vaccine

October  14th, 2020  Vancouver, British Columbia BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys”) is pleased to announce that interim results from its ongoing preclinical animal study (also known as a “murine model study”) of BXV-0320, its SARS-CoV-2 vaccine candidate, show a good emerging tolerability profile with no observed side effects or noteworthy clinical observations.  Five weeks […]

Lions Bay Announces Closing Of Final Tranche Of Non-brokered Private Placement And Provides Update On Completion Of Production And Start Of Dosing In Biovaxys’ Preclincal Study Of SARS-CoV-2 Vaccine

September 4, 2020 Vancouver, British Columbia – Lions Bay Mining Corp. (“Lions Bay” or the “Company”) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the “Private Placement”). Under the final tranche (the “Final Tranche”) of the Private Placement, the Company issued 2,954,582 units […]

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing Vancouver, British Columbia–(Newsfile Corp. – June 4, 2020) – Lions Bay Mining Corp. (CSE: LBM) (the “Company” or “Lions Bay”) is pleased to announce that it has executed a Share Exchange Agreement (the “Definitive Agreement”) with BioVaxys Inc. (previously known as BioVaxys LLC) (“BioVaxys”), […]

Lions Bay Mining Announces Update on Acquisition Target BioVaxys Initiating A SARS-CoV-2 Vaccine Study

Vancouver, British Columbia–(Newsfile Corp. – May 14, 2020) – Lions Bay Mining Corp. (CSE: LBM) (the “Company” or “Lions Bay“) is pleased to announce that it has been informed that BioVaxys LLC ( “BioVaxys”) is in the process of preparing to launch a preclinical study of its proprietary vaccine for SARS-CoV-2, the virus that causes […]

Thomas Jefferson University and BioVaxys LLC enter into exclusive worldwide license

PHILADELPHIA–(BUSINESS WIRE)–Thomas Jefferson University, a Philadelphia-based professional university with a national reputation for transdisciplinary learning and innovation, and BioVaxys LLC, a privately-held, clinical stage biotechnology company, announced today that they have entered into an exclusive worldwide license agreement for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor […]